Smith & Nephew 3Q Sales Falls to $952M

Smith & Nephew has reported third-quarter sales of $952 million, down from the $1.03 billion reported last year, according to a Bloomberg Businessweek report.

Advertisement

The sales decline was attributed to revenue loss from its biologics and clinical therapies business line, which spun off and was branded Bioventus. Broken out by business line, sales from Smith & Nephew’s knee products fell 1 percent, while its sports medicine products saw an 8 percent hike.

More Articles on Orthopedic Devices:

NeuroMetrix Signs Distribution Agreement for Pain Management Device

10 New Spine Device Launches

ConforMIS Moves Corporate Headquarters

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

  • VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

Advertisement

Comments are closed.